TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26374907

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nasal Intermittent Positive-Pressure Ventilation (NIPPV)
Number of subjects: 80
Study: 23279918

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI) in conjunction with Traditional Oral Health Education (TOHE) (n = 29)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional Oral Health Education (TOHE) alone (n = 27)
Number of subjects: 56
Study: 18723519

Group type: COMPARATOR
Intervention: Inhibited pacing (INH; basal rate 40 bpm/hysteresis 30 bpm; n = 38)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DDDR pacing with optimized atrioventricular delay (OPT; stimulation rate 65-120 bpm, n = 39)
Number of subjects: 77
Study: 16749288

Group type: EXPERIMENTAL
Intervention: Coronary reperfusion therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic regimens adjusted for elderly patients
Number of subjects: 0
Study: 14530670

Group type: EXPERIMENTAL
Intervention: Pathologist grading of dysplasia
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Pathologist grading of human papillomavirus status
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Pathologist grading of quality of histology
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Complete agreement between original pathology and pathologists
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Analysis of 86 slides previously read by one pathologist
Number of subjects: 190
Study: 11714046

Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam (100/12.5 mg/kg every 8 h)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cefotaxime plus Metronidazole (50/7.5 mg/kg every 8 h)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cefotaxime plus Metronidazole
Number of subjects: 70
Study: 9760818

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (Lipanthyl 200 m) for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 10
Study: 7533224

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg b.i.d.)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 26
Study: 3216030

Group type: EXPERIMENTAL
Intervention: 200 mg oral tablet of dilevalol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous infusion of dilevalol
Number of subjects: 12
Study: 31423686

Group type: EXPERIMENTAL
Intervention: SCS + active PNFS
Number of subjects: 52

Group type: COMPARATOR
Intervention: SCS + inactive PNFS
Number of subjects: 52
Study: 29193419

Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) supplementation (1,800 mg hydroalcoholic extract as four tablets per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (corn starch, lactose, and avicel as four tablets per day)
Number of subjects: 50
Study: 28139163

Group type: EXPERIMENTAL
Intervention: Autologous Serum (AS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preservative Free Artificial Tear (PFAT)
Number of subjects: 0
Study: 26767232

Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope with channeled blade
Number of subjects: 50

Group type: COMPARATOR
Intervention: Airtraq
Number of subjects: 50
Study: 23278371

Group type: EXPERIMENTAL
Intervention: Mirasol-treated (MIR) PLT transfusions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard reference (REF) PLT transfusions
Number of subjects: 12
Study: 21241207

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 8 weeks (q8w)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 12 weeks (q12w)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg every 8 weeks (q8w)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Infliximab (various dosages) during the open-label extension (OLE)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Infliximab (various dosages)
Number of subjects: 112
Study: 17434171

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg pre-treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no addition of 500 mg aspirin)
Number of subjects: 200
Study: 16868496

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14765002

Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavior Scale (FrSBe) for MS group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Frontal Systems Behavior Scale (FrSBe) for HC group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Self-ratings and family ratings of behavioral changes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Physical disease progression
Number of subjects: 26
Study: 10233210

Group type: EXPERIMENTAL
Intervention: Nabumetone (1-2 g daily for up to 4 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 56
Study: 8712737

Group type: EXPERIMENTAL
Intervention: Radiotherapy + SOD 8 mgr/IM/day
Number of subjects: 448

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 448
Study: 1781870

Group type: COMPARATOR
Intervention: Zidovudine (1000 mg/day) or placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Zidovudine (500 mg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Pentamidine for primary or secondary prophylaxis
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CD4+ counts less than or equal to 0.2 x 10(9)/l before 30 November 1988
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cumulative numbers of AIDS cases among patients with sufficient CD4+ counts
Number of subjects: 111
Study: 7082523

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone 3 mg kg‐1
Number of subjects: 60
Study: 30944044

Group type: EXPERIMENTAL
Intervention: Individualised pneumoperitoneum pressure strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pneumoperitoneum pressure strategy
Number of subjects: 0
Study: 27923181

Group type: EXPERIMENTAL
Intervention: COC (1.5mg estradiol and 2.5mg nomegestrolacetate)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: COC
Number of subjects: 202
Study: 26466202

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 1830
Study: 23848416

Group type: EXPERIMENTAL
Intervention: Adolescent assimilation
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Discrepancies between adolescent and parent family functioning reports
Number of subjects: 266
Study: 21543293

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily for one month
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for one month
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18481715

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at specific acupoints (contralateral scalp motor region, Jiquan (HT 1), Chize (LU 5), Daling (PC 7), Jianyu (LI 15), Tianjing (TE 10), Yangchi (TE 4)) for 3 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electro-stimulation treatment for 3 weeks.
Number of subjects: 60
Study: 16508254

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) meal
Number of subjects: 10
Study: 12780463

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in psychiatry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized results of RCTs to clinical practice
Number of subjects: 0
Study: 11126172

Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual acuity and macular perimetric mean sensitivity
Number of subjects: 20
Study: 8979203

Group type: EXPERIMENTAL
Intervention: Spring-loaded nasal dilator
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 34
Study: 1816663

Group type: EXPERIMENTAL
Intervention: Ambient temperature of 32-33 degrees C
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ambient temperature of 22-23 degrees C
Number of subjects: 32
Study: 6606404

Group type: EXPERIMENTAL
Intervention: Long cross‐clamp technique (Group 1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Short cross‐clamp technique (Group 2)
Number of subjects: 91
Study: 3490992

Group type: EXPERIMENTAL
Intervention: CSF-HU
Number of subjects: 24

Group type: COMPARATOR
Intervention: HSA
Number of subjects: 24
Study: 29660924

Group type: EXPERIMENTAL
Intervention: Fluid restrictive regimen with norepinephrine administration up to 0.04μg/kg/min (FRV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberal fluid administration (LFA)
Number of subjects: 0
Study: 26722003

Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 17387
Study: 24941835

Group type: EXPERIMENTAL
Intervention: Yupingfeng Powder (YP) combined with routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine treatment (inhaled corticosteroids and/or leukotriene regulator)
Number of subjects: 156
Study: 22512510

Group type: EXPERIMENTAL
Intervention: Social Communication Intervention Project (SCIP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 88
Study: 20553601

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18254721

Group type: EXPERIMENTAL
Intervention: 4-week exercise training intervention (individualized cardiorespiratory and resistance exercise, 150 min of moderate-intensity exercise per week)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 4-week exercise training intervention
Number of subjects: 132
Study: 15968840

Group type: EXPERIMENTAL
Intervention: Functional cognitive-behavioural therapy (FCBT)
Number of subjects: 0
Study: 12716807

Group type: EXPERIMENTAL
Intervention: Modem group (transmit blood glucose data every 2 weeks for 6 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard of care with quarterly clinic visits)
Number of subjects: 70
Study: 10594471

Group type: EXPERIMENTAL
Intervention: SDZ RAD (0.25, 0.75, 2.5, 7.5, 15, 25 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SDZ RAD (2.5-25 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SDZ RAD (0.25-25 mg)
Number of subjects: 54
Study: 8618008

Group type: EXPERIMENTAL
Intervention: SDZ 281‐240 (macrolide)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Potent halogenated corticosteroid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2011703

Group type: EXPERIMENTAL
Intervention: Diet and Senna laxative (X‐prep) combined with a saline enema (n = 88)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol electrolyte lavage solution (Golytely) (n = 90)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Combined regimen of Cascara‐Salax laxative (PicoSalax) and Golytely (n = 93)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Regimen II (Golytely)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Outpatients
Number of subjects: 271
Study: 7073570

Group type: EXPERIMENTAL
Intervention: Topical indomethacin administration before and after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 0
Study: 31054015

Group type: EXPERIMENTAL
Intervention: transcranial random noise stimulation (tRNS)
Number of subjects: 17
Study: 30128656

Group type: EXPERIMENTAL
Intervention: CRNNFA with EEMF spectral profiles of Catechol, Hydroquinone, Indole, and Tryptophan mixtures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRNNFA with TSFS spectral profiles of Benzo[a] Pyrene, Chrysene, and Pyrene mixtures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRNNFA with both EEMF and TSFS data sets
Number of subjects: 0
Study: 25759942

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training (ACT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard treatment (reflection seminars)
Number of subjects: 113
Study: 24937510

Group type: EXPERIMENTAL
Intervention: Student team visitation
Number of subjects: 330

Group type: COMPARATOR
Intervention: Limited intervention (control group)
Number of subjects: 330
Study: 22759866

Group type: EXPERIMENTAL
Intervention: 100 mg levobupivacaine (group L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol (group T)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol plus 100 mg levobupivacaine (group LT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 80
Study: 20499203

Group type: EXPERIMENTAL
Intervention: Biofeedback retraining (BFB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Partial division of puborectalis (PDPR)
Number of subjects: 60
Study: 17620671

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Both groups (TVR vs no TVR)
Number of subjects: 1955
Study: 15598194

Group type: EXPERIMENTAL
Intervention: Primary medical care (≥ 2 visits)
Number of subjects: 391
Study: 11505416

Group type: EXPERIMENTAL
Intervention: TRAUMEEL S (mouth rinse, 5 times daily for a minimum of 14 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (mouth rinse, 5 times daily for a minimum of 14 days)
Number of subjects: 32
Study: 9052357

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine pretreatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 68
Study: 7966526

Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 259

Group type: COMPARATOR
Intervention: Newborns (cord blood)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Newborns
Number of subjects: 259

Group type: COMPARATOR
Intervention: Post-partum women
Number of subjects: 259
Study: 3670227

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 MRC U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31373922

Group type: EXPERIMENTAL
Intervention: Losartan and amlodipine
Number of subjects: 142

Group type: COMPARATOR
Intervention: Losartan and hydrochlorothiazide
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study: 28727491

Group type: EXPERIMENTAL
Intervention: POC Xpert MTB/RIF test performed at a primary health care clinic
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Xpert MTB/RIF test performed at a district hospital laboratory
Number of subjects: 1297
Study: 24433306

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23984604

Group type: EXPERIMENTAL
Intervention: Patients after recent ACS (group I)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy subjects (group II)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients after ACS
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 86
Study: 21948782

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Walking Training (WT)
Number of subjects: 34
Study: 19781416

Group type: EXPERIMENTAL
Intervention: Early abciximab administration (EA) in high-risk patients (n = 413)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Late abciximab administration (LA) in high-risk patients (n = 203)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Early abciximab administration (EA) in low-risk patients (n = 314)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Late abciximab administration (LA) in low-risk patients (n = 156)
Number of subjects: 1650
Study: 16407020

Group type: COMPARATOR
Intervention: Liquid supper
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate solution
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PEG‐ELS
Number of subjects: 200
Study: 15584844

Group type: EXPERIMENTAL
Intervention: False positive normative feedback, no opportunity to reaffirm self-concept
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: False negative normative feedback, no opportunity to reaffirm self-concept
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: False positive normative feedback, opportunity to reaffirm self-concept
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: False negative normative feedback, opportunity to reaffirm self-concept
Number of subjects: 160
Study: 11237929

Group type: EXPERIMENTAL
Intervention: Fish oil (1 g EPA plus DHA daily, containing 720 mg EPA + 280 mg DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oil (80:20 mix of palm and sunflower seed oils)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ALA (2 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GLA (770 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AA (680 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DHA (720 mg daily)
Number of subjects: 0
Study: 8986685

Group type: EXPERIMENTAL
Intervention: Transdermal administration of 100 micrograms/d E2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8362228

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no M. catarrhalis)
Number of subjects: 40
Study: 3496948

Group type: EXPERIMENTAL
Intervention: Dipyridamole (120 mg/d) by constant intravenous infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic dextrose solution
Number of subjects: 24
Study: 30508890

Group type: EXPERIMENTAL
Intervention: Protocol A (90 kVp/395 mAs, contrast agent dosage of 1.2 mL/kg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Protocol B (120 kVp/200 mAs, contrast agent dosage of 1.5 mL/kg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Protocol A (90 kVp)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both Protocols
Number of subjects: 118
Study: 27077342

Group type: EXPERIMENTAL
Intervention: Computerized Women on the Road to Health (WORTH)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Traditional WORTH
Number of subjects: 306

Group type: COMPARATOR
Intervention: Wellness Promotion control group
Number of subjects: 306
Study: 25190051

Group type: EXPERIMENTAL
Intervention: hCG stimulation in patients with SCD
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (relatives and normal individuals)
Number of subjects: 15
Study: 23357439

Group type: EXPERIMENTAL
Intervention: FFT-High Risk version (FFT-HR; 12 sessions of psychoeducation and training in communication and problem-solving skills)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Education control (EC; 1-2 family sessions)
Number of subjects: 40
Study: 21357965

Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti method (plaster change three times per week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Ponseti method (plaster change weekly)
Number of subjects: 40
Study: 18070980

Group type: EXPERIMENTAL
Intervention: Levofloxacin, 1,000 mg daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Gatifloxacin, 400 mg daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Moxifloxacin, 400 mg daily
Number of subjects: 29
Study: 16826112

Group type: EXPERIMENTAL
Intervention: Removal of the subchondral bone plate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Retention of the subchondral bone plate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 14679153

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (n = 360)
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: CMF followed by goserelin (n = 357)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Goserelin alone (n = 346)
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Sequential therapy (CMF -> goserelin)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Chemotherapy alone (for ER-positive patients)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Goserelin alone (for ER-positive patients)
Number of subjects: 1063
Study: 11127233

Group type: EXPERIMENTAL
Intervention: Insecticide-treated nets (ITNs) with permethrin, 0.5 g/m2
Number of subjects: 3666

Group type: EXPERIMENTAL
Intervention: Insecticide-treated chaddars with permethrin, 1 g/m2
Number of subjects: 3666

Group type: EXPERIMENTAL
Intervention: Residual spraying of houses with lambdacyhalothrin, 30 mg/m2
Number of subjects: 3666

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3666
Study: 8617578

Group type: EXPERIMENTAL
Intervention: 6S-LV
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6R,S-LV
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-FU with 6S-LV
Number of subjects: 50
Study: 2678876

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 949903

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate cream or ointment
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.0125% flurandrenolone cream or ointment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: clobetasone butyrate
Number of subjects: 100
Study: 30824364

Group type: EXPERIMENTAL
Intervention: Trained inmate peer educators providing health education and active case finding in intervention prisons (n=8)
Number of subjects: 18032

Group type: COMPARATOR
Intervention: Existing passive case finding system in control prisons (n=8)
Number of subjects: 18032